Immunotherapy guided by urine DNA for high risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a very high risk type of bladder cancer that hasn't spread into the muscle layer and cannot be completely removed with standard surgery through the urethra
- You are not able or choose not to have your bladder removed
- You have at least one tumor that can be seen on a camera test in the bladder, and you can provide urine samples for special DNA testing
- You are in generally good health (able to care for yourself) and have normal organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a urine test for tumor DNA/RNA can help guide the decision for a second surgery in people with high-risk, non-muscle-invasive bladder cancer. It aims to see if the urine test can predict who needs the second surgery, potentially avoiding unnecessary procedures.
This trial studies if a urine test for tumor DNA can help decide when a second surgery is needed for early stage bladder cancer. It may reduce unnecessary procedures for some patients.
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This study uses urine “omics” tests (detailed lab patterns from urine) to predict whether immunotherapy will work for people with metastatic urothelial (bladder/urinary tract) cancer. It may help doctors choose the right treatment sooner by identifying who is more likely to benefit.
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.